News
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
10 Apr 24
Analyst Color, Biotech, Equities, Large Cap, News, Health Care, Price Target, Reiteration, Analyst Ratings, Trading Ideas, General
Needham Reiterates Buy on Vaxcyte, Maintains $95 Price Target
10 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
12 Mar 24
News, Price Target, Markets, Analyst Ratings, Trading Ideas
Mizuho Maintains Buy on Vaxcyte, Raises Price Target to $113
12 Mar 24
News, Price Target, Analyst Ratings
Vaxcyte Completes Enrollment Of Phase 2 Study Evaluating VAX-24 For Prevention Of Invasive Pneumococcal Disease In Infants
4 Mar 24
Biotech, News, General
Needham Maintains Buy on Vaxcyte, Raises Price Target to $95
28 Feb 24
News, Price Target, Analyst Ratings
Recap: Vaxcyte Q4 Earnings
27 Feb 24
Earnings
Vaxcyte Q4 2023 GAAP EPS $(1.82) Misses $(1.07) Estimate
27 Feb 24
Earnings, Earnings Misses, News
Earnings Scheduled For February 27, 2024
27 Feb 24
Earnings